List of Excipients in Branded Drug ZEPOSIA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Celgene Corporation	ZEPOSIA	ozanimod hydrochloride	59572-820	CELLULOSE, MICROCRYSTALLINE	2029-05-14
Celgene Corporation	ZEPOSIA	ozanimod hydrochloride	59572-820	CROSCARMELLOSE SODIUM	2029-05-14
Celgene Corporation	ZEPOSIA	ozanimod hydrochloride	59572-820	MAGNESIUM STEARATE	2029-05-14
Celgene Corporation	ZEPOSIA	ozanimod hydrochloride	59572-820	SILICON DIOXIDE	2029-05-14

ZEPOSIA Excipient Strategy and Commercial Opportunities

Last updated: September 24, 2026

ZEPOSIA (ozanimod hydrochloride) is an oral, once-daily sphingosine-1-phosphate receptor modulator marketed by Bristol Myers Squibb for relapsing forms of multiple sclerosis and moderately to severely active ulcerative colitis. Its commercial formulation is a low-dose hard capsule with a relatively conventional excipient system: microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium and magnesium stearate, with colored gelatin capsule shells.[1]

The largest excipient opportunities are in generic and lifecycle formulations rather than in direct substitution of a single incumbent material. Suppliers can compete on low-dose content uniformity, flow, blend segregation, capsule-color reproducibility, moisture control, global regulatory support and manufacturing scale. The commercial opportunity is strongest for excipients that improve uniformity and process robustness without changing the approved dosage form.

What is ZEPOSIA and which dosage forms use excipients?

ZEPOSIA contains ozanimod hydrochloride. The marketed product is supplied as hard capsules in three strengths:

Strength	Ozanimod hydrochloride content	Capsule use
0.23 mg	0.23 mg	Initial titration
0.46 mg	0.46 mg	Titration and maintenance
0.92 mg	0.92 mg	Maintenance

The approved starter regimen begins with 0.23 mg once daily and escalates over the first week before reaching 0.92 mg once daily.[1] The dosage form is therefore commercially unusual in one respect: the product requires multiple low-dose strengths and a coordinated starter pack, not only a single maintenance capsule.

What excipients are used in ZEPOSIA capsules?

The FDA labeling identifies the core capsule-fill excipients as:

Excipient	Primary formulation function	Commercial relevance
Microcrystalline cellulose	Diluent and compression or filling aid	Controls bulk density and blend handling
Croscarmellose sodium	Disintegrant	Supports rapid capsule-fill dispersion
Colloidal silicon dioxide	Glidant and anti-caking agent	Improves flow and reduces segregation risk
Magnesium stearate	Lubricant	Controls equipment friction and ejection
Gelatin capsule shell	Dosage-form shell	Provides mechanical integrity and product identification
Capsule colorants	Product identification	Important for strength differentiation and supply continuity

The public label does not indicate an extended-release matrix, enteric coating or complex multiparticulate delivery system.[1] This limits the need for specialty release-controlling polymers but increases the importance of powder engineering and analytical control at very low drug loads.

Which excipient attributes matter most for ZEPOSIA generics?

Low-dose uniformity is the primary technical challenge. A 0.23 mg capsule contains a small amount of active pharmaceutical ingredient relative to the excipient mass. Small changes in particle-size distribution, density, electrostatic behavior or mixing energy can cause content-uniformity failures.

Microcrystalline cellulose

Microcrystalline cellulose is likely to be the largest-volume excipient in the capsule blend. Suppliers can differentiate through:

• Narrow particle-size distribution
• Controlled bulk and tapped density
• Low variability in moisture content
• Low electrostatic charging
• Consistent grades for capsule filling
• Direct regulatory support across the United States, European Union and emerging markets

A co-processed microcrystalline cellulose grade may provide a commercial advantage if it improves powder flow or reduces segregation. The risk is regulatory: a new co-processed excipient system may require additional comparative development work and may complicate generic sameness arguments.

Colloidal silicon dioxide

Colloidal silicon dioxide is a small-quantity but high-impact process aid. Its performance depends on surface area, dispersion and mixing sequence. Excessive silica can alter blend flow, capsule-fill behavior and dissolution. A supplier that provides validated low-dose addition procedures, rather than only a material specification, has a stronger value proposition.

Croscarmellose sodium

Croscarmellose sodium is important for rapid dispersion of the capsule contents. Grade selection can affect swelling, wicking and dissolution. The commercial opportunity is to offer a grade with consistent substitution level, low variability in fibrous morphology and reproducible performance across different microcrystalline cellulose lots.

Magnesium stearate

Magnesium stearate presents a conventional but material risk. Over-lubrication can reduce wettability and slow dissolution. Particle morphology, specific surface area, fatty-acid profile and blending time affect performance. A supplier can compete through tighter control of lubricant functionality and process studies supporting short lubrication cycles.

How should a generic manufacturer design a ZEPOSIA excipient strategy?

A generic developer should begin with a formulation that matches the reference product's dosage form and critical quality attributes. The main development targets are:

1. Assay and content uniformity across all three strengths.
2. Comparable dissolution profiles.
3. Capsule-fill weight consistency.
4. Physical and chemical stability.
5. Moisture and oxygen control.
6. Robust performance across commercial-scale equipment.
7. A defensible global excipient supply chain.

The formulation should be developed across the 0.23 mg, 0.46 mg and 0.92 mg strengths simultaneously. A formulation that works only at the 0.92 mg strength may fail at the 0.23 mg strength because the active-to-excipient ratio changes materially.

What manufacturing process is most suitable?

A conventional ordered-blend or geometric-dilution process is commercially plausible. The preferred process depends on the physical properties of the ozanimod hydrochloride drug substance. A typical development sequence would evaluate:

• Premixing of drug substance with a portion of microcrystalline cellulose
• Stepwise geometric dilution
• Addition of croscarmellose sodium
• Controlled addition of colloidal silicon dioxide
• Short, validated magnesium stearate lubrication
• Encapsulation under controlled humidity

Wet granulation may improve uniformity if the drug substance has poor flow or strong segregation behavior, but it adds processing steps, residual-moisture risk and cost. Dry granulation may improve flow but can change dissolution and create additional particle-size variability. Direct capsule filling is commercially attractive if blend uniformity can be maintained at scale.

What formulation patents protect ZEPOSIA?

The key intellectual-property questions are whether a generic applicant must address drug-substance patents, composition patents, formulation patents or method-of-use patents. FDA-approved drug products with relevant patents are listed in the Orange Book, which remains the principal source for FDA patent-listing analysis.[2]

For ZEPOSIA, the most commercially relevant patent categories are:

Patent category	Potential scope	Relevance to excipient strategy
Drug-substance patents	Ozanimod compounds, salts and stereochemical forms	May block the active ingredient regardless of excipient selection
Solid-state patents	Crystalline forms, polymorphs or hydrates	Can affect drug-substance sourcing and stability
Pharmaceutical-composition patents	Capsules or compositions containing ozanimod	May limit formulation design-around options
Method-of-use patents	Multiple sclerosis and ulcerative colitis treatment	Can affect labeling and Paragraph IV litigation
Manufacturing patents	Drug-substance or intermediate synthesis	May restrict API supply routes
Packaging and stability claims	Moisture, oxygen or light protection	Can affect commercial packaging but usually does not create a separate excipient barrier

The active-ingredient and use patents typically pose a larger legal risk than the listed excipients themselves. Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate are established compendial materials. A generic applicant normally seeks to use them without relying on proprietary rights held by the excipient manufacturer.

When does ZEPOSIA lose exclusivity?

ZEPOSIA received FDA approval in March 2020 for multiple sclerosis and a supplemental approval in October 2021 for ulcerative colitis.[1] The five-year new chemical entity exclusivity period associated with the original approval ran approximately through March 2025, subject to FDA-specific calculations and any pediatric exclusivity.[3]

Patent expiry dates may extend beyond regulatory exclusivity. Generic entry therefore depends on the remaining Orange Book patents, patent-term adjustments, patent-term extension, Paragraph IV certifications and any litigation settlement. A loss of NCE exclusivity does not itself establish immediate generic availability.

What is the Orange Book status of ZEPOSIA?

The Orange Book identifies patents and regulatory exclusivity associated with approved products. A generic applicant must evaluate the listed patents when filing an ANDA, including whether to submit Paragraph III certifications, Paragraph IV certifications or a section viii statement for method-of-use claims.[2]

For an excipient-focused commercial assessment, the critical questions are:

• Whether any listed patent claims the capsule composition itself.
• Whether the claims require a particular excipient combination.
• Whether a generic can omit or change the claimed excipient.
• Whether the dosage form, strength and administration schedule are protected.
• Whether method-of-use patents can be carved out through labeling.
• Whether a patent dispute could delay launch after ANDA approval.

A formulation design that changes only the grade or supplier of a compendial excipient may not avoid a composition claim if the claim covers the same functional combination. Conversely, a true excipient substitution may provide a design-around if the patent requires a specific material or concentration range.

Which companies are challenging ZEPOSIA patents?

Public generic competition should be assessed through FDA ANDA activity, Paragraph IV litigation filings and district-court dockets. No commercial conclusion should rely solely on the existence of a formulation alternative. The relevant competitor may challenge the drug substance, use claims or formulation claims instead of pursuing an excipient-based design-around.

Potential entrants are likely to include:

• Large generic manufacturers with neurology and immunology portfolios
• European and Indian ANDA filers
• Contract manufacturers developing low-dose hard-capsule platforms
• Specialty generics companies targeting multiple sclerosis and ulcerative colitis

The absence of a public litigation event does not prove that no Paragraph IV filing exists. FDA patent certifications are not fully visible through a single public database, and litigation may be filed after an applicant sends a Paragraph IV notice.

What commercial opportunities exist for excipient suppliers?

1. Low-dose uniformity platforms

The strongest opportunity is a coordinated excipient system designed for low-dose encapsulation. Suppliers can offer:

• High-flow microcrystalline cellulose
• Low-variability croscarmellose sodium
• Functionalized colloidal silicon dioxide
• Controlled-grade magnesium stearate
• Formulation screening packages
• Blend-uniformity and scale-up support

The value proposition is reduced development time and lower batch-failure risk, not simply a lower per-kilogram price.

2. Starter-pack supply

ZEPOSIA requires multiple strengths during titration. This creates an opportunity for contract packagers and capsule suppliers that can support:

• Three capsule strengths
• Strength-specific color coding
• Combination starter packs
• Serialization and tamper-evident packaging
• Global artwork and language variants
• Inventory coordination across multiple SKUs

Packaging complexity can become a larger commercial constraint than the cost of the excipient blend.

3. Capsule-shell alternatives

Gelatin capsule suppliers can compete on color consistency, mechanical strength, brittleness, moisture transfer and global supply capacity. Hypromellose capsules could be evaluated for vegetarian positioning, moisture performance or supply diversification, but a shell substitution would require comparative quality and stability work.

Capsule-shell colorants also have commercial significance. A new color system can create identification and regulatory comparability issues across markets. Strength differentiation should remain clear for patients and pharmacists.

4. Modified formulations

A lifecycle product could pursue a simplified titration package, alternative capsule strengths, orally disintegrating technology or a different solid oral dosage form. Such products would face clinical, regulatory and intellectual-property barriers. An excipient change alone would generally not justify a new product strategy unless it improves adherence, stability, tolerability or manufacturing economics.

How does ZEPOSIA compare with competing oral immunomodulators?

ZEPOSIA competes with oral therapies such as fingolimod, dimethyl fumarate, diroximel fumarate, teriflunomide and ponesimod in multiple sclerosis, and with oral or biologic therapies in ulcerative colitis. The competitive excipient opportunity differs by product:

Product type	Formulation complexity	Excipient opportunity
Immediate-release low-dose capsule	Moderate process sensitivity	Blend uniformity and capsule supply
Delayed-release dimethyl fumarate	Higher coating complexity	Enteric polymers and coating systems
Film-coated tablets	Moderate	Compression, coating and stability
Biologics	High	Parenteral excipients, containers and cold-chain systems
S1P receptor modulators	Variable	Low-dose uniformity, titration packs and packaging

ZEPOSIA is more accessible to conventional solid-dose excipient suppliers than biologics, but its low-dose, multistrength presentation creates technical requirements that exceed those of a single-strength conventional capsule.

What FDA regulatory issues affect ZEPOSIA excipient selection?

FDA review will focus on pharmaceutical equivalence, bioequivalence, product quality and manufacturing reproducibility. Key regulatory considerations include:

• Compliance with applicable USP-NF monographs
• Supplier qualification and change control
• Elemental impurity assessment under ICH Q3D
• Nitrosamine risk assessment where chemically relevant
• Residual solvents and microbiological controls
• Extractables and leachables from capsules and packaging
• Stability under ICH conditions
• Dissolution comparability
• Content-uniformity validation
• Justification for any noncompendial or co-processed excipient

ICH Q8, Q9 and Q10 support a quality-by-design approach that links material attributes to critical quality attributes and process parameters.[4-6] For ZEPOSIA, the most defensible development package would demonstrate that excipient variability does not materially alter assay, content uniformity, dissolution or stability.

How strong is the ZEPOSIA patent estate?

The estate should be considered layered rather than dependent on one excipient claim. Drug-substance, formulation, manufacturing and method-of-use rights can create separate barriers. The practical strength of the estate depends on:

• Remaining patent term
• Claim breadth
• Patent-term adjustment or extension
• Validity under obviousness and written-description standards
• Availability of noninfringing formulations
• Ability to use a section viii labeling carve-out
• Commercial attractiveness of an at-risk launch

For excipient suppliers, the patent risk is usually indirect. Their customers, rather than the suppliers, generally bear the ANDA certification and infringement risk. Suppliers should still conduct freedom-to-operate reviews where they offer a proprietary co-processed system or formulation package that could be characterized as practicing a patent claim.

What generic launch scenarios exist for ZEPOSIA?

Three launch scenarios are commercially credible:

Scenario	Description	Excipient impact
First-wave conventional generic	Same capsule architecture with comparable excipients	Highest demand for qualified commodity and functional excipients
Design-around generic	Different grade, capsule shell or excipient system	Greater development work and stronger demand for technical support
Authorized or partnered generic	Product supplied through an originator or license arrangement	Lower patent risk but tighter supply and specification control

The most likely cost advantage will come from manufacturing yield, blend robustness, packaging efficiency and supply-chain scale rather than from replacing a low-cost excipient with another low-cost excipient.

Key Takeaways

• ZEPOSIA is a low-dose, multistrength hard-capsule product containing ozanimod hydrochloride.
• Its core excipient system is conventional, but the 0.23 mg strength creates demanding content-uniformity requirements.
• Microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide and magnesium stearate are the main formulation targets for supplier differentiation.
• Starter-pack assembly, capsule-shell supply and color consistency create separate commercial opportunities.
• Generic developers should optimize all three strengths together rather than develop only the 0.92 mg maintenance strength.
• The main legal barriers are likely to arise from active-ingredient, formulation, manufacturing and method-of-use patents, not from ordinary compendial excipient ownership.
• The strongest supplier proposition combines excipient material, process support, scale-up data and global regulatory documentation.
• A conventional generic, a formulation design-around and a partnered or authorized generic represent distinct launch pathways.

FAQs

Can ZEPOSIA use a different capsule shell?

Yes. A different shell, including hypromellose, may be technically feasible, but the applicant must demonstrate comparable performance, stability, identification and product quality.

Which excipient is most important for ZEPOSIA content uniformity?

Microcrystalline cellulose is likely to have the largest overall effect because of its role as the principal diluent, but colloidal silicon dioxide, mixing sequence and drug-substance particle properties can also materially affect uniformity.

Does ZEPOSIA require an enteric coating?

The FDA-approved ZEPOSIA capsule is not described as an enteric-coated or extended-release dosage form. Its formulation relies on immediate capsule-fill dispersion rather than a delayed-release coating.[1]

Are excipient substitutions likely to avoid ZEPOSIA patents?

They may avoid a narrow composition claim directed to a specific excipient or concentration, but they will not necessarily avoid drug-substance, manufacturing or method-of-use patents. Each proposed formulation requires claim-by-claim analysis.

Is the larger opportunity in ZEPOSIA excipients or packaging?

For a generic launch, packaging can be as commercially important as the excipient blend because the product requires multiple strengths, titration instructions, color differentiation and coordinated starter-pack presentation.

References

1. U.S. Food and Drug Administration. (2024). ZEPOSIA (ozanimod) capsules, prescribing information. Bristol Myers Squibb.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2024). Regulatory exclusivity and patent-term information for approved drug products. https://www.fda.gov/drugs

4. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development.

5. International Council for Harmonisation. (2005). ICH Q9: Quality risk management.

6. International Council for Harmonisation. (2008). ICH Q10: Pharmaceutical quality system.